(Q45171313)

English

The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk

scientific article published in January 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

The apoB/apoA-I ratio is better than the cholesterol ratios to estimate the balance between plasma proatherogenic and antiatherogenic lipoproteins and to predict coronary risk (English)

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Allan D Sniderman

6

object named as

Allan D Sniderman

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

author name string

Göran Walldius

1

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Ingmar Jungner

2

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Are H Aastveit

3

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Ingar Holme

4

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Curt D Furberg

5

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

publication date

1 January 2004

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Clinical Chemistry and Laboratory Medicine

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

42

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

12

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

1355-1363

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS).

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.254

21 January 2018

Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.254

21 January 2018

The Friedewald formula underestimates LDL cholesterol at low concentrations

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.254

21 January 2018

Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.254

21 January 2018

Metabolic origins and clinical significance of LDL heterogeneity

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.254

21 January 2018

Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.254

21 January 2018

Applying apoB to the diagnosis and therapy of the atherogenic dyslipoproteinemias: a clinical diagnostic algorithm

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.254

21 January 2018

Nonfasting apolipoprotein B and triglyceride levels as a useful predictor of coronary heart disease risk in middle-aged UK men.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.254

21 January 2018

European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice.

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.254

21 January 2018

Value of HDL cholesterol, apolipoprotein A-I, lipoprotein A-I, and lipoprotein A-I/A-II in prediction of coronary heart disease: the PRIME Study. Prospective Epidemiological Study of Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.254

21 January 2018

Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Québec cardiovascular study

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.254

21 January 2018

Measurement issues related to lipoprotein heterogeneity

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.254

21 January 2018

Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.254

21 January 2018

Hypertriglyceridemic hyperapob: the unappreciated atherogenic dyslipoproteinemia in type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.254

21 January 2018

Emerging therapeutic strategies for the management of dyslipidemia in patients with the metabolic syndrome

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.254

21 January 2018

Apolipoprotein B and A-I in relation to serum cholesterol and triglycerides in 43,000 Swedish males and females

1 reference

https://api.crossref.org/works/10.1515%2FCCLM.2004.254

21 January 2018

Identifiers

10.1515/CCLM.2004.254

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

10 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45171313&oldid=2069021807"